Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for managing type 2 diabetes mellitus, though certain formulations are now licensed for weight management in adults with obesity or overweight with comorbidities
These effects are directly proportional to dietary fat intake, which some proponents argue actually helps enforce dietary compliance
GIP treatment has been shown to reduce glucolipotoxicity-induced cell death in C57 BL/6 and Bax -/- pancreatic islets, but not GIPR -/- pancreatic islets of the mouse models (114)
By law, any form of bodily introduction of this product into humans or animals is strictly prohibited
Weight loss effects vary by population, with approximately 5-11% in diabetes trials and 15-21% in obesity trials (SURMOUNT program) at the highest doses
Mental health symptoms, including depression and suicidal ideation, should be assessed regularly, as these may occur in the context of eating disorders regardless of treatment